glaxosmithkline saw profits fall 9 last year £62bn 115bn europes biggest drugmaker says recovery 2005 way
cheap copies drugs particularly antidepressants paxil wellbutrin weak dollar hit profits global sales 1 2004
firm confident new pipeline deliver profits despite failure obesity
chief executive jeanpierre garnier said difficult year
early afternoon trade london company share price 1 1218 pence
mr garnier said company absorbed £15bn lost sales generics still managing grow business
continuing success key products means look forward good performance 2005 said
2005 important year terms research development pipeline progress however firm discontinued development experimental treatment obesity known 771 disappointing clinical trial results
glaxo relying new treatments conditions cancer diabetes depression hivaids allergies lift pace sales growth several disappointing years

